MYC and lymphoma: The origin of these mutations in lymphomas is uncertain, but MYC is a predicted target of the aberrant somatic hypermutation machinery (aSHM), which displays a high affinity for the genomic regions around the transcription start site (TSS) of transcriptionally active genes.